Brian Elsbernd - Feb 15, 2024 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Compliance/Legal Officer
Signature
/s/ Brian Elsbernd
Stock symbol
CPRX
Transactions as of
Feb 15, 2024
Transactions value $
$0
Form type
4
Date filed
2/16/2024, 05:00 PM
Previous filing
Dec 29, 2023
Next filing
Mar 28, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise +9.67K +6.8% 152K Feb 15, 2024 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Tax liability -2.35K -1.55% 149K Feb 15, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Restricted Stock Units Options Exercise $0 -9.67K -0.95% $0.00 1.01M Feb 15, 2024 Common Stock 9.67K Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2 Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units.
F3 Derivative securities vest in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025.
F4 Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on February 15, 2024.